Das Wiener Allgemeine Krankenhaus ist das Universitätsklinikum der Stadt Wien. Es ist eines der größten Krankenhäuser Europas und das größte Krankenhaus Österreichs. Außerdem ist es Sitz der Medizinischen Universität Wien.

During the past decade, Akh Wien conducted 89 clinical trials. In the 10-year time frame, 89 clinical trials started and 45 clinical trials were completed, i.e. on average, 50.6% percent of trials that started reached the finish line to date. In the past 5 years, 44 clinical trials started and 37 clinical trials were completed. i.e. 84.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Akh Wien" #1 sponsor was "Bayer" with 21 trials, followed by "Amgen" with 12 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 12 trials sponsored, "Eli Lilly and Company" with 11 trials sponsored and "Boston Scientific Corporation" with 11 trials sponsored. Other sponsors include 93 different institutions and companies that sponsored additional 75 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Akh Wien" #1 collaborator was "Incyte Corporation" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Amgen" with 2 trials as a collaborator, "Arbeitsgruppe Lebermetastasen und Tumoren" with 2 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 2 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 59 trials.

According to Clinical.Site data, the most researched conditions in "Akh Wien" are "Heart Failure" (6 trials), "Colorectal Cancer" (5 trials), "Crohn's Disease" (5 trials), "Lymphoma" (4 trials) and "Atopic Dermatitis" (3 trials). Many other conditions were trialed in "Akh Wien" in a lesser frequency.

Most popular intervention types in "Akh Wien" are "Drug" (119 trials), "Device" (24 trials), "Procedure" (21 trials), "Other" (17 trials) and "Biological" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "fluorouracil" (6 trials), "leucovorin calcium" (6 trials), "Baricitinib" (5 trials) and "conventional surgery" (5 trials). Other intervention names were less common.

The vast majority of trials in "Akh Wien" are 144 trials for "All" genders, 13 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Akh Wien". undefined are not yet recruiting, 17 are recruiting, 26 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 93 completed trials in Akh Wien, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Akh Wien, 11 "Phase 1" clinical trials were conducted, 53 "Phase 2" clinical trials and 64 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 14 trials that are defined as “Not Applicable".

Akh Wien has several departments that took part in Clinical trials: "AKH Wien, Universitaetsklinik fuer Innere Medizin III" - 14 trials, "AKH Wien | Allg. Gynaekologie & gynaekologische Onkologie" - 2 trials, "AKH, Klinik für Urologie der Universität Wien" - 2 trials, "Klin. Abt. für Onkologie, AKH Wien" - 2 trials